.png)
Global Biopharmaceutical Company
Global Market Access, International Strategy Leadership
Established Multi-Asset Portfolio
Rare Disease
Subscribe to our newsletter to receive the latest case studies.
Global Biopharmaceutical Company
Global Market Access, International Strategy Leadership
Established Multi-Asset Portfolio
Rare Disease
A global biopharmaceutical company wanted to strengthen the strategic narrative for an established rare disease portfolio in a rapidly evolving treatment landscape.
Existing evidence, messaging, and prior strategic work were spread across multiple assets and audiences, making it difficult to communicate a clear portfolio-level story.
The client engaged Alkemi to synthesize the existing work and develop a concise narrative that could support future internal alignment and external communication.
1. Reviewed existing strategy, messaging, evidence, and prior communications across the portfolio.
2. Organized the portfolio narrative around clinical, patient, economic, and broader value considerations.
3. Facilitated a leadership working session to refine messages, assess evidence gaps, and align on priorities.
4. Translated the outputs into an executive-ready narrative and recommendations for future validation, evidence development, and stakeholder engagement.
Create one clear portfolio story that could guide future strategy and communication.
“It has been a pleasure working with the Alkemi team on this initiative. Thank you for your collaboration, responsiveness, and support throughout the project.” - Senior Director, Global Market Access.
Established a consistent narrative for use across functions and audiences.
Clarified how the established portfolio fit within a changing treatment landscape.
Identified evidence and messaging needs to guide future research, communication, and stakeholder engagement.